• Corpus ID: 80397157

Alkaptonuria - An obscure disease

@inproceedings{Lamas2016AlkaptonuriaA,
  title={Alkaptonuria - An obscure disease},
  author={Joana Lamas},
  year={2016}
}
.............................................................................................................................5 Resumo..............................................................................................................................6 Introduction ........................................................................................................................7 Materials and Methods… 

Figures from this paper

References

SHOWING 1-10 OF 60 REFERENCES

Progress in Alkaptonuria – are we near to an effective therapy?

The opportunity to modulate the tyrosine pathway by employing nitisinone brings with it considerations of the most appropriate time of life to begin treatment, both to minimise cost and to prevent unnecessary exposure to risk of toxicity.

Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients

Clinical and molecular findings in 29 alkaptonuric patients from mainland France and the Reunion Island and the first AKU mutation described in a black subject are reported, which suggests that the HGD haplotype is an old mutation that probably originated in Africa and spread throughout Eurasia during human migrations.

An update on molecular genetics of Alkaptonuria (AKU)

  • A. Zatkova
  • Medicine
    Journal of Inherited Metabolic Disease
  • 2011
The genetic aspects of AKU in general and the distribution of all known disease-causing mutations reported so far are summarized and focused on special features ofAKU in Slovakia, which is one of the countries with an increased incidence of this rare metabolic disorder.

Recent advances in management of alkaptonuria (invited review; best practice article)

A potential disease modifying drug, nitisinone, inhibits 4-hydroxy-phenyl-pyruvate-dioxygenase and decreases formation of HGA and could prevent or slow the progression of disease in AKU.

Natural history of alkaptonuria.

Although nitisinone can reduce HGA production in humans with homogentisate 1,2-dioxygenase deficiency, the long-term safety and efficacy of this treatment require further evaluation.

Identification of alkaptonuria in the general population: a United Kingdom experience describing the challenges, possible solutions and persistent barriers

Strategies used included a questionnaire survey of general practitioners, a dedicated website and patient network contact, targeted family screening and medical conference targeting, which identified 75 patients in the UK with AKU.

Mutation Screening of the HGD Gene Identifies a Novel Alkaptonuria Mutation with Significant Founder Effect and High Prevalence

The founder effect and high degree of consanguineous marriages have contributed to AKU among nomads, which seems to be highly increased in people of nomadic origin.

The pathology of alkaptonuric ochronosis.

Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations.

Using computational approaches based on the 3D structure, these novel mutations are predicted to affect the activity of the protein complex through destabilisation of the individual protomer structure or through disruption of protomer-protomer interactions.
...